JP2023052688A5 - - Google Patents

Download PDF

Info

Publication number
JP2023052688A5
JP2023052688A5 JP2023010833A JP2023010833A JP2023052688A5 JP 2023052688 A5 JP2023052688 A5 JP 2023052688A5 JP 2023010833 A JP2023010833 A JP 2023010833A JP 2023010833 A JP2023010833 A JP 2023010833A JP 2023052688 A5 JP2023052688 A5 JP 2023052688A5
Authority
JP
Japan
Prior art keywords
tcr
chain
modified
βr44w
βq44k
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023010833A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023052688A (ja
Filing date
Publication date
Priority claimed from DE102016123893.7A external-priority patent/DE102016123893A1/de
Application filed filed Critical
Publication of JP2023052688A publication Critical patent/JP2023052688A/ja
Publication of JP2023052688A5 publication Critical patent/JP2023052688A5/ja
Priority to JP2025014650A priority Critical patent/JP2025063330A/ja
Pending legal-status Critical Current

Links

JP2023010833A 2016-12-08 2023-01-27 対合が改善されたｔ細胞受容体ｔ細胞 Pending JP2023052688A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025014650A JP2025063330A (ja) 2016-12-08 2025-01-31 対合が改善されたｔ細胞受容体ｔ細胞

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662497895P 2016-12-08 2016-12-08
DE102016123893.7 2016-12-08
US62/497,895 2016-12-08
DE102016123893.7A DE102016123893A1 (de) 2016-12-08 2016-12-08 T-Zellrezeptoren mit verbesserter Bindung
PCT/EP2017/081745 WO2018104407A1 (en) 2016-12-08 2017-12-06 T cell receptors with improved pairing
JP2019529260A JP7346294B2 (ja) 2016-12-08 2017-12-06 対合が改善されたｔ細胞受容体ｔ細胞

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019529260A Division JP7346294B2 (ja) 2016-12-08 2017-12-06 対合が改善されたｔ細胞受容体ｔ細胞

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025014650A Division JP2025063330A (ja) 2016-12-08 2025-01-31 対合が改善されたｔ細胞受容体ｔ細胞

Publications (2)

Publication Number Publication Date
JP2023052688A JP2023052688A (ja) 2023-04-11
JP2023052688A5 true JP2023052688A5 (https=) 2023-12-19

Family

ID=60937683

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023010833A Pending JP2023052688A (ja) 2016-12-08 2023-01-27 対合が改善されたｔ細胞受容体ｔ細胞
JP2025014650A Pending JP2025063330A (ja) 2016-12-08 2025-01-31 対合が改善されたｔ細胞受容体ｔ細胞

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025014650A Pending JP2025063330A (ja) 2016-12-08 2025-01-31 対合が改善されたｔ細胞受容体ｔ細胞

Country Status (9)

Country Link
US (1) US20250163124A1 (https=)
EP (1) EP4317432A3 (https=)
JP (2) JP2023052688A (https=)
KR (2) KR102379955B1 (https=)
CL (1) CL2019001536A1 (https=)
CO (1) CO2019006901A2 (https=)
IL (1) IL267130A (https=)
NZ (1) NZ754222A (https=)
PH (1) PH12019501243A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111936954B (zh) * 2018-04-17 2024-03-08 株式会社和冠 具备后端部连接器的电子笔用笔芯

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10225139A1 (de) 2002-05-29 2004-02-26 Immatics Biotechnologies Gmbh Verfahren zur Identifizierung von immunreaktiven Peptiden
DE10225144A1 (de) 2002-05-29 2003-12-18 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
DE10313819A1 (de) 2003-03-24 2004-10-07 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
WO2005076009A2 (en) 2004-01-28 2005-08-18 Immatics Biotechnologies Gmbh Method for identifying and quantifying of tumour-associated peptides
DE102004026135A1 (de) 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
ES2367643T3 (es) 2005-04-26 2011-11-07 Immatics Biotechnologies Gmbh Identificador de un epítopo de linfocitos t presentado por el antígeno hla-a2 y derivado de la proteína del receptor de laminina inmadura del antígeno oncofetal y usos de este.
SI1806358T1 (sl) 2005-09-05 2010-06-30 Immatics Biotechnologies Gmbh S tumorjem povezani peptidi ki se promiskuitetnovežejo na molekule humanega levkocitnega antigena HLA razreda II
EP1760089B1 (en) 2005-09-05 2009-08-19 Immatics Biotechnologies GmbH Tumor-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules and related anti-cancer vaccine
CN103864893B (zh) 2007-07-27 2017-01-04 伊玛提克斯生物技术有限公司 免疫疗法的免疫抗原表位
HUE032379T2 (en) 2007-07-27 2017-09-28 Immatics Biotechnologies Gmbh Composition of tumour-associated peptides and related anti-cancer vaccine
HRP20150820T1 (xx) 2007-07-27 2015-09-11 Immatics Biotechnologies Gmbh Nova imunoterapija protiv neuronskih tumora i tumora mozga
ES2532896T5 (es) 2008-05-14 2018-03-20 Immatics Biotechnologies Gmbh Péptidos del MHC de clase II novedosos y potentes derivados de survivina y neurocan
RS53782B1 (sr) 2008-10-01 2015-06-30 Immatics Biotechnologies Gmbh Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera
GB0917094D0 (en) * 2009-09-29 2009-11-11 Ucl Biomedica Plc T-cell receptor
WO2011073215A2 (en) 2009-12-14 2011-06-23 Immatics Biotechnologies Gmbh Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
GB201004575D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201019331D0 (en) 2010-03-19 2010-12-29 Immatics Biotechnologies Gmbh Methods for the diagnosis and treatment of cancer based on AVL9
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
GB201009222D0 (en) 2010-06-02 2010-07-21 Immatics Biotechnologies Gmbh Improved cancer therapy based on tumour associated antigens derived from cyclin D1
GB201015765D0 (en) 2010-09-21 2010-10-27 Immatics Biotechnologies Gmbh Use of myeloid cell biomarkers for the diagnosis of cancer
GB201021289D0 (en) 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
CA2821582A1 (en) 2010-12-14 2012-06-21 Immatics Biotechnologies Gmbh Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
GB2508414A (en) * 2012-11-30 2014-06-04 Max Delbrueck Centrum Tumour specific T cell receptors (TCRs)
US9937207B2 (en) 2013-03-21 2018-04-10 Sangamo Therapeutics, Inc. Targeted disruption of T cell receptor genes using talens
TWI636065B (zh) 2013-08-05 2018-09-21 伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
GB201408255D0 (en) 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
GB201411037D0 (en) 2014-06-20 2014-08-06 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
WO2016071343A1 (en) 2014-11-03 2016-05-12 Immures S.R.L. T cell receptors
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
GB201423361D0 (en) 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
GB201504502D0 (en) 2015-03-17 2015-04-29 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
GB201505585D0 (en) 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
GB201507030D0 (en) 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
GB201507719D0 (en) 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
GB201510771D0 (en) 2015-06-19 2015-08-05 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer
GB201511191D0 (en) 2015-06-25 2015-08-12 Immatics Biotechnologies Gmbh T-cell epitopes for the immunotherapy of myeloma
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
GB201511792D0 (en) 2015-07-06 2015-08-19 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers
MY189596A (en) 2015-07-15 2022-02-18 Immatics Biotechnologies Gmbh A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
GB201515321D0 (en) 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
GB201517538D0 (en) 2015-10-05 2015-11-18 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
HK1258444A1 (zh) 2015-10-09 2019-11-15 Immatics Biotechnologies Gmbh 抗wt1/hla特异性抗体
GB201521746D0 (en) 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
GB201521894D0 (en) 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
GB201522667D0 (en) 2015-12-22 2016-02-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers

Similar Documents

Publication Publication Date Title
JP2020500525A5 (https=)
US20210380659A1 (en) T cell receptors with improved pairing
JP2023506757A5 (https=)
JP2018015010A5 (https=)
JP2020537644A5 (https=)
JP2019522490A5 (https=)
JP2020512019A5 (https=)
JP2020511936A5 (https=)
JP2020511152A (ja) Ｐｒａｍｅ陽性がんに対するｔ細胞受容体およびそれを用いた免疫療法
JP2006526414A5 (https=)
JP2012500006A5 (https=)
JP2019521169A5 (https=)
JP2023052688A5 (https=)
JP2025063330A5 (https=)
JP2023133505A5 (https=)
JP2024507540A5 (https=)
CN111741746A (zh) 治疗自身免疫性疾病的方法
JPH10501267A (ja) 制限化ペプチド
JP2024515066A5 (https=)
JP2021524451A5 (https=)
Pham et al. In vivo expansion of antigen-specific regulatory T cells through staggered Fc. IL-2 mutein dosing and antigen-specific immunotherapy
JP2024038256A5 (https=)
US20250163124A1 (en) T cell receptors with improved pairing
JP2022519293A5 (https=)
JP2022502078A5 (https=)